Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,351 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Breathe 2 Project 3: Comprehensive Chronic Care

NCT05382221
View directory record Official record
Conditions
Smoking Cessation, Smoking Abstinence
Interventions
Comprehensive Chronic Care, Standard Care
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 7:50 AM EDT
Not listed Not applicable Interventional

Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer

NCT00956670
View directory record Official record
Conditions
Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer, Stage IA Vulvar Cancer, Stage IB Cervical Cancer, Stage IB Uterine Corpus Cancer, Stage IB Vulvar Cancer, Stage II Uterine Corpus Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IVB Vulvar Cancer
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors, Therapeutic Conventional Surgery, Therapeutic Laparoscopic Surgery, Therapeutic Lymphadenectomy
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
213
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Not applicable Interventional

CTSI-iPad for Vented Patient Communication

NCT03163823
View directory record Official record
Conditions
Respiratory Failure
Interventions
Proloquo2Go, Standard of Care
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

NCT00398827
View directory record Official record
Conditions
Anesthesia, Surgical Procedures, Elective
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Loma Linda, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

NCT01388361
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin aspart, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
48
States / cities
Concord, California • La Jolla, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

NCT02452554
View directory record Official record
Conditions
Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Interventions
Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study
Other · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

NCT00003641
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
interferon alfa-2b, observation
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2026
U.S. locations
511
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks

NCT00705705
View directory record Official record
Conditions
HIV Infections
Interventions
Network leader training, Standard HIV risk-reduction counseling
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Nirogacestat in Ovarian Granulosa Cell Tumors

NCT05348356
View directory record Official record
Conditions
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
Interventions
Nirogacestat
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642
View directory record Official record
Conditions
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Interventions
AZD0486 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Tampa, Florida • Louisville, Kentucky • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 1 Interventional

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 31, 2026, 7:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 31, 2026, 7:50 AM EDT
Terminated Phase 3 Interventional Results available

An Open Label Study for Participants With Rheumatoid Arthritis

NCT01215942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00023673
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, three-dimensional conformal radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
40
States / cities
Mobile, Alabama • Phoenix, Arizona • Burbank, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions
lisocabtagene maraleucel
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
59
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 31, 2026, 7:50 AM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
80
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

NCT01696461
View directory record Official record
Conditions
Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions
Plerixafor
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 31, 2026, 7:50 AM EDT
Terminated Not applicable Interventional Results available

Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and Components

NCT01992354
View directory record Official record
Conditions
Indication for a PET CT Exam
Interventions
PET MR Device
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 31, 2026, 7:50 AM EDT
Completed Not applicable Interventional Results available

Real World Expanded Multicenter Study of the MitraClip® System (REALISM)

NCT01931956
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
MitraClip® implant
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
38
States / cities
Los Angeles, California • Mountain View, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 31, 2026, 7:50 AM EDT